0.07
+2.94%
Close of 5 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About PainChek
Its shares trade on ASX under the ticker PCK.AX. It has been listed since 1 May 2012. In the fiscal year to 30 June 2026, it reported revenue of A$3.7m and a net loss of A$8.9m. At that date it held total assets of A$7.6m and shareholders' equity of −A$1.4m.
PainChek Ltd. engages in the development and commercialisation of mobile medical device applications. The company is headquartered in Sydney, New South Wales. The company went IPO on 2012-05-01. The Company’s principal activities are development and commercialization of mobile medical device applications that provide pain assessment for individuals that are unable to communicate with their carers. The Company’s PainChek Universal is a complete point-of-care solution that combines the existing PainChek Application with the numerical rating scale (NRS). PainChek Application uses artificial intelligence and facial recognition to detect pain in those who cannot self-report. This gives a voice to those who cannot verbalize pain, whilst also driving objectivity and consistency in all assessments. For those who can self-report, PainChek Universal also includes access to the NRS, a standard used to document pain levels amongst these individuals. PainChek Universal also supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Technology
- Listed since
- 1 May 2012
- Website
- painchek.com ↗
Leadership
Pay as last reported
- Mr. John MurrayNon-Executive Chairman of the BoardA$94,995
- Mr. Iain McAdamChief Financial OfficerA$393,165
- Mr. Philip DaffasManaging Director, Director, since 2016A$410,583
- Ms. Natalie ClimoCompany Secretary
- Mr. Adam DaveyNon-Executive DirectorA$47,498
- Mr. Ross HarricksNon-Executive DirectorA$47,498
- Ms. Cynthia PayneNon-Executive DirectorA$20,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- PainChek Universal combines AI facial recognition with NRS for objective pain assessment.
- PainChek Ltd. has been listed on the ASX since 2012 with strong market presence.
- PainChek Application uses AI to detect pain in non-verbal patients, providing critical care insights.
Weaknesses
- PainChek Ltd. relies solely on mobile medical device applications without diversification.
- The company's focus on AI facial recognition may face technological limitations in diverse populations.
- PainChek Universal requires integration with existing healthcare systems for full adoption.
Opportunities
- Expanding into the Australian healthcare sector with PainChek Universal's point-of-care solution.
- Growing demand for AI-driven pain assessment tools in aged care facilities.
- Increasing adoption of mobile medical applications in the Health Care sector.
Threats
- Competition from established healthcare technology firms in the Health Care industry.
- Regulatory changes affecting mobile medical device applications in Australia.
- Potential market saturation in the niche pain assessment technology segment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.